Clinical Trial Update: Study of ARO-APOC3 in Adults With Dyslipidemia [Phase 2]

View source ↗

Summary

Arrowhead Pharmaceuticals reports that the Phase 2 trial of ARO-APOC3 in adults with dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• ARO-APOC3 (APOC3 antisense oligonucleotide)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Dyslipidemias | Phase 2 | Status: COMPLETED